AI-powered contentSome parts of this article are powered by AI.
Share this article
Gotrade News - Altimmune (ALT) reported a net loss of $31.6 million, or $0.15 per share, for the third quarter ended September 30, 2026, compared with $19.0 million, or $0.21 per share, a year earlier, according to Altimmune's official release on Thursday, November 12, 2026.
Regular-session close on November 12, 2026, New York time. Prices and changes: Yahoo Finance, cross-checked against the closing price on Nasdaq.com. Market cap: that close times the shares outstanding on the latest 10-Q or 10-K cover (SEC EDGAR).
Altimmune Earnings Details
Research and development expenses were $27.0 million for the three months ended September 30, 2026, compared with $15.0 million in the same period in 2025, the release said. R&D expenses for the quarter included $20.3 million in direct costs related to pemvidutide development activities.
General and administrative expenses were $8.7 million, compared with $5.9 million a year earlier, and interest income was $4.8 million. Altimmune reported cash, cash equivalents and investments totaling $480 million as of September 30, 2026.
"We continue to make significant progress across all our clinical development programs, as we execute our strategy of building a liver franchise around pemvidutide," Chief Executive Officer and Chairman Jerry Durso said in the release.
Why It Matters for ALT
According to the company, the increase in R&D spending was driven primarily by the ongoing PERFORMA Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH) and the RESTORE Phase 2 trial in alcohol-associated liver disease (ALD). Both study pemvidutide, an investigational balanced 1:1 glucagon/GLP-1 dual receptor agonist. The company said PERFORMA is progressing as planned, with 52-week topline data anticipated in 2029, and that RESTORE has completed enrollment, with topline data expected in the second half of 2027.
In alcohol use disorder (AUD), the company said an End-of-Phase 2 meeting with the U.S. Food and Drug Administration is scheduled for December 2026 to discuss a Phase 3 registrational program. RECLAIM Phase 2 data in AUD were delivered in a late-breaking oral presentation at AASLD The Liver Meeting 2026. The release also said Altimmune appointed Peter Greenleaf and Alex Howarth to its Board of Directors in October 2026 and relocated its corporate headquarters to Morristown, New Jersey, in November 2026.
This article is for education and information only and is not investment advice. Investment decisions are yours to make after your own research.
This article was written with the help of AI and checked by the Gotrade team before publishing.
Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA). This content is for educational purposes only and does not constitute financial advice. Always do your own research (DYOR) before investing.
M. Alfathan Rahman is a content writer with over 3 years of experience developing digital content strategies across various industries, including fintech. He has experience producing content for tax-related websites and financial education platforms. His focus areas include data research, and crafting financial articles that are informative, accurate, and accessible to investors of all experience levels.
